PAT

Sonata Software - International Services Revenue grew by 4.6% QoQ (40% YoY) in USD, and Domestic Gross Contribution grew by 16.5% YoY in INR. Board approved 1:1 bonus issue and interim dividend of ₹ 7 per share

Retrieved on: 
Thursday, October 26, 2023
Cloud, Digital, Yoy, Sonata Software, International, GTM, Health care, CRS, EBITDA, Microsoft, MD, Quarter, Sonata, PAT, System integration, Growth, DSO, USD, TMT, Microsoft Open Specification Promise, TTH, BFSI, Food delivery, Pension fund, Iron ore, Telecommunications, Video game

BENGALURU, India, Oct. 25, 2023 /PRNewswire/ -- Sonata Software, a global IT services and technology solutions company, today reported its unaudited financial results for its 2nd quarter ended 30thSeptember 2023.

Key Points: 
  • Our International services Revenue in USD terms grew 4.6% QoQ.
  • Performance Highlights for the quarter:
    Revenues at ₹ 1,912.6 crores; YoY growth of 28%
    EBITDA at ₹ 220.5 crores; YoY growth of 33%
    PAT at ₹ 124.2 crores; YoY growth of 10%
    DSO improved to 40 days (Q1'24: 41 days).
  • Revenues at ₹ 1,244.0 crores; YoY growth of 20%
    Gross contribution at ₹ 62.4 Crs grew by 16.5% YoY.
  • EBITDA at ₹ 56.4 crores; YoY growth of 20%
    PAT at ₹ 40.5 crores; YoY growth of 19%
    DSO improved to 35 days (Q1'24: 36 days)

LumaCyte Launches New Compact Radiance® Instrument for Advanced Therapy Biomanufacturing & QC Environments

Retrieved on: 
Tuesday, October 24, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Health Technology, Other Health, Laboratory, Microfluidics, CSO, Chemical oxygen demand, Vaccine, CDMO, Organization, Doctor of Philosophy, Cell, LFC, Multimedia, PAT, Environment, Patient, Retail

The half-sized compact design is new, occupying only 16 inches of bench space, but the underlying technology remains unchanged.

Key Points: 
  • The half-sized compact design is new, occupying only 16 inches of bench space, but the underlying technology remains unchanged.
  • Utilizing LFC, LumaCyte’s Radiance® platform instrument provides real-time, label-free, quantitative cell characterization analytics for better manufacturing controls.
  • The new Radiance® instrument stands poised to meet the growing demands for advanced analytics in manufacturing and production environments.
  • Radiance®’s more compact form factor could not have come at a better time.

North America Dominates the Preclinical Imaging Market in 2022 Due to Advanced Research Infrastructure - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023
Radiology, Health, Research, Vega, National Conference, MRI, Smartphone, Scan (company), Drug discovery, Biotechnology, India, Conference, Automated Imaging Association, Infection, Kidney, PerkinElmer, Cosmetics, PET, Arietta, Cardiology, Development, PAT, Connect, Neurology, CT, Optical flow, Traction, USD, Abdominal ultrasonography, SPECT, Cancer, X-ray, Compound annual growth rate, Medical imaging

The global preclinical imaging market is poised for substantial growth, with a projected size of USD 5.95 billion by 2030.

Key Points: 
  • The global preclinical imaging market is poised for substantial growth, with a projected size of USD 5.95 billion by 2030.
  • The market is expected to expand at a Compound Annual Growth Rate (CAGR) of 4.74% from 2023 to 2030.
  • Heavy investments in research and development worldwide are driving research projects and, subsequently, the demand for preclinical imaging.
  • Advancements in high-throughput ultrasound imaging systems used in cancer research and studies have further driven market growth.

Sonata Software - International Services Revenue grew by 4.6% QoQ (40% YoY) in USD, and Domestic Gross Contribution grew by 16.5% YoY in INR. Board approved 1:1 bonus issue and interim dividend of ₹ 7 per share

Retrieved on: 
Wednesday, October 25, 2023
Cloud, Digital, Yoy, Sonata Software, International, GTM, Health care, CRS, EBITDA, Microsoft, MD, Quarter, Sonata, PAT, System integration, Growth, DSO, USD, TMT, Microsoft Open Specification Promise, TTH, BFSI, Food delivery, Pension fund, Iron ore, Telecommunications, Video game

BENGALURU, India, Oct. 25, 2023 /PRNewswire/ -- Sonata Software, a global IT services and technology solutions company, today reported its unaudited financial results for its 2nd quarter ended 30thSeptember 2023.

Key Points: 
  • Our International services Revenue in USD terms grew 4.6% QoQ.
  • Performance Highlights for the quarter:
    Revenues at ₹ 1,912.6 crores; YoY growth of 28%
    EBITDA at ₹ 220.5 crores; YoY growth of 33%
    PAT at ₹ 124.2 crores; YoY growth of 10%
    DSO improved to 40 days (Q1'24: 41 days).
  • Revenues at ₹ 1,244.0 crores; YoY growth of 20%
    Gross contribution at ₹ 62.4 Crs grew by 16.5% YoY.
  • EBITDA at ₹ 56.4 crores; YoY growth of 20%
    PAT at ₹ 40.5 crores; YoY growth of 19%
    DSO improved to 35 days (Q1'24: 36 days)

Sonata Software - International Services Revenue grew by 4.6% QoQ (40% YoY) in USD, and Domestic Gross Contribution grew by 16.5% YoY in INR. Board approved 1:1 bonus issue and interim dividend of ₹ 7 per share

Retrieved on: 
Wednesday, October 25, 2023
Cloud, Digital, Yoy, Sonata Software, International, GTM, Health care, CRS, EBITDA, Microsoft, MD, Quarter, Sonata, PAT, System integration, Growth, DSO, USD, TMT, Microsoft Open Specification Promise, TTH, BFSI, Food delivery, Pension fund, Iron ore, Telecommunications, Video game

BENGALURU, India, Oct. 25, 2023 /PRNewswire/ -- Sonata Software, a global IT services and technology solutions company, today reported its unaudited financial results for its 2nd quarter ended 30thSeptember 2023.

Key Points: 
  • Our International services Revenue in USD terms grew 4.6% QoQ.
  • Performance Highlights for the quarter:
    Revenues at ₹ 1,912.6 crores; YoY growth of 28%
    EBITDA at ₹ 220.5 crores; YoY growth of 33%
    PAT at ₹ 124.2 crores; YoY growth of 10%
    DSO improved to 40 days (Q1'24: 41 days).
  • Revenues at ₹ 1,244.0 crores; YoY growth of 20%
    Gross contribution at ₹ 62.4 Crs grew by 16.5% YoY.
  • EBITDA at ₹ 56.4 crores; YoY growth of 20%
    PAT at ₹ 40.5 crores; YoY growth of 19%
    DSO improved to 35 days (Q1'24: 36 days)

Optical Imaging Leads Global Preclinical Imaging Market with 13.6% Share in 2022

Retrieved on: 
Friday, October 20, 2023
Research, Vega, National Conference, MRI, Smartphone, Scan (company), Drug discovery, Biotechnology, India, Conference, Automated Imaging Association, Infection, Kidney, PerkinElmer, Cosmetics, PET, Arietta, Cardiology, Development, PAT, Connect, Neurology, CT, Optical flow, Traction, USD, Abdominal ultrasonography, SPECT, Cancer, X-ray, Compound annual growth rate, Medical imaging

The global preclinical imaging market is poised for substantial growth, with a projected size of USD 5.95 billion by 2030.

Key Points: 
  • The global preclinical imaging market is poised for substantial growth, with a projected size of USD 5.95 billion by 2030.
  • The market is expected to expand at a Compound Annual Growth Rate (CAGR) of 4.74% from 2023 to 2030.
  • Heavy investments in research and development worldwide are driving research projects and, subsequently, the demand for preclinical imaging.
  • Preclinical imaging finds applications across a wide range of sectors, including pharmaceuticals, biotechnology, life sciences, medical devices, cosmetics, veterinary hospitals, and educational institutions.

SentrySciences ParticleSentryAI Receives 2023 Pharma Innovation Award

Retrieved on: 
Wednesday, October 18, 2023
PAT, SME, AI, Aggregation, Process analytical technology, Software, Root cause analysis, Fine chemical, Medical imaging

LONGMONT, Colo., Oct. 18, 2023 /PRNewswire-PRWeb/ -- The Pharma Innovation Awards are an annual celebration of new technologies and services that help advance product quality, risk reduction and manufacturing efficiency. The awards seek to highlight companies who listen to the needs of the market and their customers, and as a result, have distinguished themselves as leaders in pharma equipment and technology. The awards will be showcased in Pharma Manufacturing's November issue.

Key Points: 
  • SentrySciences is proud to announce that our software product, ParticleSentryAI is a recipient of the 2023 Pharma Innovation Award.
  • LONGMONT, Colo., Oct. 18, 2023 /PRNewswire-PRWeb/ -- The Pharma Innovation Awards are an annual celebration of new technologies and services that help advance product quality, risk reduction and manufacturing efficiency.
  • ParticleSentryAI software brings AI and subvisible particle imaging technologies together to provide a foundation for protein aggregate control strategies in the development and manufacture of biologic drugs.
  • ParticleSentryAI leverages morphological and textural features encoded in each image to understand the causes of aggregation and deliver actionable data to limit their impact.

Retired USMC Sgt. Jonathan Lubecky joins Veterans Exploring Treatment Solutions (VETS) as Legislative Director, Underscoring Commitment to Reform

Retrieved on: 
Wednesday, October 18, 2023
TBI, Foundationalism, Congress, Policy, Hotel del Coronado, Education, Stanford University, Department of Defense Serum Repository, United States Department of Veterans Affairs, Psychiatry, Research, Spouse, NDAA, MC, PAT, PTSD, Legislature, Behavioural sciences, Special Operations Warrior Foundation, Luttrell, 2008 Colorado Amendment 48, Survivor, National Defense Authorization Act, National security, House, Hotel, Associate, Mental health, Nursing, Veterinary medicine, Pharmaceutical industry, MD, Health, Neuroscience, Veteran

WASHINGTON , Oct. 18, 2023 /PRNewswire-PRWeb/ -- Veterans Exploring Treatment Solutions (VETS), a leading non-profit organization dedicated to ending veteran suicide, today announced the appointment of retired USMC Sgt. Jonathan Lubecky as Legislative Director to lead VETS' policy reform and advocacy efforts.

Key Points: 
  • Jonathan Lubecky as Legislative Director to lead VETS' policy reform and advocacy efforts.
  • Jonathan's appointment to Legislative Director underscores VETS' commitment to furthering these efforts.
  • Jonathan Lubecky said, "Joining VETS in its mission to bridge the gap in veterans' access to life-saving mental health care is an honor.
  • For more information or to become a sponsor, please visit vetsolutions.org/gala or download the Sponsorship Brochure .

Tata Elxsi delivers healthy growth in Q2 FY'24 with revenue from operations growing at 3.7% QoQ and 15.5% YoY, and EBITDA margin at 29.9%

Retrieved on: 
Tuesday, October 17, 2023
BSE, Automotive industry, Health care, Profit (accounting), Per stirpes, Net income, Communication, Quarter, SDV, EPS, Traction, Yoy, Transport, RS, EBITDA, Original equipment manufacturer, NSE, Growth, Industrial design, PAT, PBT, Airline, Bookkeeping, Video game

BANGALORE, India, Oct. 17, 2023 /PRNewswire/ -- Tata Elxsi (BSE: 500408) (NSE: TATAELXSI), amongst the world's leading providers of design led technology services, announced its second quarter results for the period ending 30th September 2023.

Key Points: 
  • 881.7 Cr of operating revenue, a growth of 15.5% over the same quarter of previous year (YoY).
  • Transportation growth at 7.1% QoQ, 26.1% YoY, aided by large deals and strong traction in Software Defined Vehicle (SDV) engagements.
  • Our EBITDA has grown 4.8% QoQ and 16.3% YoY and our EBITDA margin has improved by 31 bps to 29.9%.
  • Our Transportation business, which accounts for 46.2% of the revenue coming from three verticals, witnessed strong growth of 7.1% QoQ and 26.1% YoY.

OYO Reports its first net profit at RM9 million

Retrieved on: 
Thursday, October 12, 2023
24/7 service, Letter, Cash flow, US, DanCenter, OYO, EBITDA, Tourism, RM9, US–UK Mutual Defence Agreement, Travel, EBIDTA, Moody's Investors Service, Growth, Fitch, Annual report, PAT, Operation Active Endeavour, GBV, City, CFO, Online shopping, SEA, Palette

In a letter to the company's top management, founder Ritesh Agarwal shared that Q2 FY2024 has turned out to be company's maiden profitable quarter with profit after tax (PAT) of over RM9 million (approx).

Key Points: 
  • In a letter to the company's top management, founder Ritesh Agarwal shared that Q2 FY2024 has turned out to be company's maiden profitable quarter with profit after tax (PAT) of over RM9 million (approx).
  • Agarwal, during an employee town hall earlier this year, also shared that OYO expects to clock Adjusted EBITDA of nearly RM455 million in FY2024.
  • Its Adjusted Gross Profit Margin rose to 43% of revenue, and its Adjusted Gross Profit increased by 23% to RM1333 million in FY23 from RM1088 million in FY22.
  • Recently, global ratings agency Moody's (Moody's Investors Service) shared that it expects OYO to remain EBITDA positive for FY24.